In vivo tracking of dendritic cells in patients with multiple myeloma

Simple item page
dc.contributor.authorPrince, HMen_AU
dc.contributor.authorWall, DMen_AU
dc.contributor.authorRitchie, Den_AU
dc.contributor.authorHonemann, Den_AU
dc.contributor.authorHarrisson, Sen_AU
dc.contributor.authorQuach, Hen_AU
dc.contributor.authorThompson, Men_AU
dc.contributor.authorHicks, RJen_AU
dc.contributor.authorLau, EWen_AU
dc.contributor.authorDavison, Jen_AU
dc.contributor.authorLoudovaris, Men_AU
dc.contributor.authorBartholeyns, Jen_AU
dc.contributor.authorKatsifis, Aen_AU
dc.contributor.authorMileshkin, Len_AU
dc.contributor.authorMoloney, Jen_AU
dc.contributor.authorLoveland, Ben_AU
dc.date.accessioned2020-03-23T23:22:18Zen_AU
dc.date.available2020-03-23T23:22:18Zen_AU
dc.date.issued2008-02-01en_AU
dc.description.abstractDendritic cell (DC) immunotherapy is being actively studied in multiple myeloma (MM). We aimed to use positron emission tomography or single positron emission tomography to determine the in vivo distribution of monocyte-derived nonmatured DC or matured DC (mDC) administered to patients with MM. Eligible patients had stable or slowly progressive MM and elevated serum MUC-1 or MUC-1 expression on marrow plasma cells. DCs were derived from granulocyte-macrophage colony-stimulating factor+ interleukin-13 stimulated autologous monocytes, pulsed with mannan-MUC1 fusion protein, and matured by FMKp and interferon-gamma. Before injection, DCs were labeled with either 18fluorine-fluorodeoxyglucose, 111indium-oxine or 64copper-pyruvaldehyde-bis-N-4-methylthiosemicarbazone. Labeled DCs were given either as a single intravenous dose or by concurrent subcutaneous (SC), intradermal (ID), and intranodal routes. 18Fluorine-fluorodeoxyglucose tracking was unsuccessful owing to high radiolabel efflux. 64Copper-pyruvaldehyde-bis-N-4-methylthiosemicarbazone-labeled mDC (n=2 patients) demonstrated tracking to regional nodes but quantitation was also limited owing to cellular efflux. 111Indium-oxine, however, gave reproducible tracking of both nmDc and mDC (n=6) to regional lymph node after either SC or ID administration, with mDC revealing superior migration to regional lymph node. SC and ID routes produced similar levels of DC migration. © 2008 by Lippincott Williams & Wilkinsen_AU
dc.identifier.citationPrince, H. M., Wall, D. M., Ritchie, D., Honemann, D., Harrrison, S., Quach, H., Thompson, M., Hicks, R., Lau, E., Davison, J., Loudovaris, M., Moloney, J., Loveland, B., Bartholeyns, J., Katsifis, A., & Mileshkin, L. (2008). In vivo tracking of dendritic cells in patients with multiple myeloma. Journal of Immunotherapy, 31(2), 166-179. doi:10.1097/CJI.0b013e31815c5153en_AU
dc.identifier.govdoc8864en_AU
dc.identifier.issn1524-9557en_AU
dc.identifier.issue2en_AU
dc.identifier.journaltitleJournal of Immunotherapyen_AU
dc.identifier.pagination166-179en_AU
dc.identifier.urihttps://doi.org/10.1097/CJI.0b013e31815c5153en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/9198en_AU
dc.identifier.volume31en_AU
dc.language.isoenen_AU
dc.publisherLippincott Williams & Wilkinsen_AU
dc.subjectIn vivoen_AU
dc.subjectSingle photon emission computed tomographyen_AU
dc.subjectRadiopharmaceuticalsen_AU
dc.subjectImmunotherapyen_AU
dc.subjectPositron computed tomographyen_AU
dc.subjectNeoplasmsen_AU
dc.titleIn vivo tracking of dendritic cells in patients with multiple myelomaen_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles